PRESS RELEASE
News
-
-
-
PRESS RELEASE
CBI continues to implement its ACE strategy during December 2025
CBI continues to implement its ACE strategy during December 2025, maintaining stable mining returns in Bitcoins and exceeding 13% per annum in USD. The company aims to expand its server fleet and remains focused on holding Bitcoins for potential market rebound -
PRESS RELEASE
THX Pharma annonce la nomination de Julien Veys au poste de Directeur général adjoint
Nomination de Julien Veys en tant que Directeur général adjoint chez THX Pharma, société spécialisée dans les maladies neurologiques rares. Stratégie d'enregistrement et commercialisation internationale de médicaments -
-
-
PRESS RELEASE
Drone DriX H-9: Exail annonce deux nouvelles commandes, dont une intégrant des capacités anti-drones aériens
Exail annonce la signature de deux contrats pour son drone de surface DriX H-9, accélérant son adoption dans la défense et la sécurité maritime. Les innovations incluent la capacité CUAS pour neutraliser les drones aériens et renforcer la cartographie des fonds marins -
PRESS RELEASE
DriX H-9 drone: Exail announces two new orders, one of which integrates aerial anti-drone capabilities
Exail announces signing of two contracts for its DriX H-9 surface drone, accelerating adoption of autonomous solutions in maritime defense and security. CUAS capability for countering air threats and SHOM order for seabed mapping highlight system's versatility and operational relevance -
PRESS RELEASE
Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai -
